AbCellera Q4 2019 Earnings Report
Key Takeaways
AbCellera's Q4 2021 revenue reached $139.3 million, with royalties on bamlanivimab sales contributing $134.5 million and research fees accounting for $4.7 million. Net earnings for the quarter were $59.9 million, or $0.21 per share on a basic and $0.19 per share on a diluted basis.
Q4 2021 revenue was $139.3 million, representing 37% of the total for 2021.
Royalties on net sales of bamlanivimab generated $134.5 million in Q4 2021.
Research fees contributed $4.7 million in Q4 2021.
Net earnings for Q4 2021 were $59.9 million, or $0.21 per share on a basic and $0.19 per share on a diluted basis.
AbCellera
AbCellera
AbCellera Revenue by Segment
Forward Guidance
AbCellera moves into 2022 with momentum and a strong cash position to continue to grow our business and to make investments that will increase the speed, efficiency, and scalability of our platform.